Galderma’s Aesthetic Edge: Why This Dermatology Leader Deserves 35% Upside
By stockpickr AI | March 16, 2026 | 10 min read
Investment Summary
Galderma is a global leader in medical dermatology, commanding a strong position in injectable aesthetics and therapeutic skincare.
Investment Recommendation
Buy
Fair Value: $33.35
Current Price: $24.65
Upside/Downside: +35.3%
No recommendation provided
Key Metrics
- Market Cap: $19.85B
- P/E Ratio: 32.4
- Dividend Yield: 0.65%
- Analyst Target Price: $98.50
Strengths
- Dominant market position in the high-growth injectable aesthetics segment.
- Strong R&D pipeline focused on premium skincare and rare skin disease therapeutics.
- High brand loyalty and physician preference for Restylane and Dysport products.
Risk Factors
- High regulatory scrutiny regarding safety profiles of cosmetic injectables.
- Intense competition from established pharmaceutical giants in dermatology.
- Sensitivity to consumer spending levels in elective aesthetic procedures.
Latest News
Galderma revenue growth exceeds expectations on strong aesthetics demand
Galderma reported robust quarterly earnings, driven by resilient demand for aesthetic treatments across its key global markets.
Source: Reuters | Sentiment: Very Positive